Market Overview

400th Lombard Medical Aorfix(TM) Endovascular Stent Graft Procedure Completed One Year Following Japanese Approval and Launch


Lombard Medical, Inc. (NASDAQ: EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that within a year of the Aorfix™ regulatory approval in Japan, physicians have completed approximately 400 cases – or an estimated 5 percent of all AAA cases in Japan. Aorfix received approval from the Japanese Ministry of Health, Labour and Welfare in August 2014, and is the first and only endovascular stent graft with worldwide regulatory approvals for the treatment of patients with aortic neck angulations up to 90 degrees.

Lombard CEO Simon Hubbert commented, "The adoption of Aorfix by the vascular surgery community in Japan has been extremely encouraging, as has been the outstanding commercial execution displayed by our distribution partners at Medico's Hirata. We look forward to the continued adoption of Aorfix in this important and growing market as well as other global markets."

Japan is the world's second largest standalone EVAR market; it was estimated at $140 million or 10 percent of the global market in 2013 and has been growing at an average rate of 18 percent over the last five years. There are approximately 400 physicians at 200 clinics performing EVAR in Japan, and it is estimated that around 55 percent of Japanese AAA patients are treated using this minimally invasive method.1

Posted-In: News FDA Press Releases


Related Articles (EVAR)

View Comments and Join the Discussion!

VMware: FBR Believes Improving Emerging Technologies Remains Criticals To Generate Licence Revenue & Billings Growth

Alibaba Launches "Tmall Vineyard Direct" Program through the Opening of the Robert Mondavi Wines Exclusive Flagship Store on